HRP20090569T1 - Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja - Google Patents
Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja Download PDFInfo
- Publication number
- HRP20090569T1 HRP20090569T1 HR20090569T HRP20090569T HRP20090569T1 HR P20090569 T1 HRP20090569 T1 HR P20090569T1 HR 20090569 T HR20090569 T HR 20090569T HR P20090569 T HRP20090569 T HR P20090569T HR P20090569 T1 HRP20090569 T1 HR P20090569T1
- Authority
- HR
- Croatia
- Prior art keywords
- effective amount
- pharmaceutical composition
- composition according
- bifeprunox mesylate
- bifeprunox
- Prior art date
Links
- ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 title claims 10
- 239000002552 dosage form Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65414905P | 2005-02-18 | 2005-02-18 | |
| PCT/EP2006/060055 WO2006087369A1 (en) | 2005-02-18 | 2006-02-17 | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090569T1 true HRP20090569T1 (hr) | 2009-11-30 |
Family
ID=36383746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090569T HRP20090569T1 (hr) | 2005-02-18 | 2009-10-26 | Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7423040B2 (de) |
| EP (1) | EP1853232B1 (de) |
| AT (1) | ATE439831T1 (de) |
| CA (1) | CA2598407A1 (de) |
| DE (1) | DE602006008583D1 (de) |
| DK (1) | DK1853232T3 (de) |
| ES (1) | ES2331487T3 (de) |
| HR (1) | HRP20090569T1 (de) |
| PL (1) | PL1853232T3 (de) |
| PT (1) | PT1853232E (de) |
| SI (1) | SI1853232T1 (de) |
| WO (1) | WO2006087369A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7964604B2 (en) * | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| US20080132520A1 (en) * | 2006-08-31 | 2008-06-05 | Winsemius Antje A | Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds |
| US20090068290A1 (en) * | 2006-08-31 | 2009-03-12 | Michel Bourin | Bifeprunox doses for treating schizophrenia |
| EP2059244A1 (de) * | 2006-08-31 | 2009-05-20 | Solvay Pharmaceuticals B.V. | Titrationsplan für bifeprunox zur behandlung von schizophrenie und kits zur verwendung damit |
| US20100119622A1 (en) * | 2008-09-15 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor |
| EP2377850A1 (de) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1-Vanilloidrezeptorantagonisten mit einem bizyklischen Teil |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586794T2 (de) | 1984-12-21 | 1993-05-27 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
| PL189256B1 (pl) | 1996-03-29 | 2005-07-29 | Duphar Int Res | Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków |
| TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
| UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| CA2310950C (en) | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| AR045362A1 (es) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| CA2581143C (en) | 2004-09-21 | 2015-03-31 | Shandong Luye Pharmaceutical Co., Ltd. | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| KR20080046205A (ko) | 2005-08-22 | 2008-05-26 | 솔베이 파마슈티칼스 비. 브이 | 프로드럭으로서 피페라진 및 피페리딘 유도체의 ｎ-산화물 |
-
2006
- 2006-02-16 US US11/354,652 patent/US7423040B2/en not_active Expired - Fee Related
- 2006-02-17 DK DK06708346T patent/DK1853232T3/da active
- 2006-02-17 AT AT06708346T patent/ATE439831T1/de active
- 2006-02-17 CA CA002598407A patent/CA2598407A1/en not_active Abandoned
- 2006-02-17 ES ES06708346T patent/ES2331487T3/es active Active
- 2006-02-17 EP EP06708346A patent/EP1853232B1/de active Active
- 2006-02-17 WO PCT/EP2006/060055 patent/WO2006087369A1/en active Application Filing
- 2006-02-17 PL PL06708346T patent/PL1853232T3/pl unknown
- 2006-02-17 PT PT06708346T patent/PT1853232E/pt unknown
- 2006-02-17 SI SI200630444T patent/SI1853232T1/sl unknown
- 2006-02-17 DE DE602006008583T patent/DE602006008583D1/de active Active
-
2009
- 2009-10-26 HR HR20090569T patent/HRP20090569T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060194812A1 (en) | 2006-08-31 |
| US7423040B2 (en) | 2008-09-09 |
| SI1853232T1 (sl) | 2010-01-29 |
| CA2598407A1 (en) | 2006-08-24 |
| PL1853232T3 (pl) | 2010-01-29 |
| ES2331487T3 (es) | 2010-01-05 |
| WO2006087369A1 (en) | 2006-08-24 |
| DE602006008583D1 (de) | 2009-10-01 |
| DK1853232T3 (da) | 2009-12-14 |
| PT1853232E (pt) | 2009-11-12 |
| ATE439831T1 (de) | 2009-09-15 |
| EP1853232B1 (de) | 2009-08-19 |
| EP1853232A1 (de) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090569T1 (hr) | Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja | |
| JP5386173B2 (ja) | 閉経前の性的欲求障害の治療のためのフリバンセリンの使用 | |
| DK2021006T3 (en) | USE OF flibanserin in postmenopausal SEXLYSTFORSTYRRELSER | |
| JP2019505525A (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| AU2013248685B2 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| ES2579857T3 (es) | Composiciones de plasma rico en plaquetas | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| RS52583B (en) | TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORO-N- (HINUCLIDIN-3-IL) BENZO [B] THIOPHENE-2-CARBOXAMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| JP2021505575A5 (de) | ||
| US6620851B2 (en) | Methods for the treatment of neuropathic pain and other disorders using R(−)-ketoprofen | |
| JP2005530787A5 (de) | ||
| CN106029637A (zh) | 新的组合物 | |
| JP5259181B2 (ja) | うつ病または不安神経症の予防または治療剤 | |
| JP2023022243A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| JPWO2015046484A1 (ja) | 骨粗鬆症治療剤 | |
| JPH08504203A (ja) | パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用 | |
| AR045362A1 (es) | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona | |
| JP2016188260A (ja) | 五淋散エキス配合製剤 | |
| ES2864176T3 (es) | Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua | |
| JP6230519B2 (ja) | 五淋散エキス配合製剤 | |
| JP2010518040A (ja) | 不眠症を治療するためのフリバンセリンの使用 | |
| JP2004161636A (ja) | 軽度認知障害または注意欠陥多動性障害治療剤 | |
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. | |
| AR126082A1 (es) | Formas de dosificación farmacéuticas que comprenden 3-(5-metil-1,3-tiazol-2-ilo)-5-[(3r)-tetra-hidrofuran-3-iloxi]-n-(1r)-1-[2-(trifluorometil)pirimidin-5-ilo]etil-benzamida | |
| JP2010235549A (ja) | 五淋散エキス配合製剤 |